Related Experiment Video
Updated: Jul 7, 2026
07:17
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Neoadjuvant therapy for pancreatic cancer
1Surgery, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0987, USA. alowy@ucsd.edu
Summary
Neoadjuvant therapy is being explored for pancreatic cancer, offering a potential improvement over traditional adjuvant treatments. Further research and clinical trials are needed to establish its efficacy compared to standard postoperative care.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Pancreatic cancer surgery (resection) is often insufficient for a cure.
- Traditional adjuvant (postoperative) therapies show limited success in improving outcomes.
- Neoadjuvant (preoperative) strategies are emerging for various cancers.
Purpose of the Study:
- To discuss the rationale for neoadjuvant therapy in pancreatic cancer.
- To review existing data on both adjuvant and neoadjuvant treatments.
- To highlight ongoing clinical trials for neoadjuvant therapy.
Main Methods:
- Literature review of adjuvant and neoadjuvant therapies for pancreatic cancer.
- Discussion of the theoretical basis for neoadjuvant treatment strategies.
- Analysis of the current landscape of clinical trials in neoadjuvant pancreatic cancer therapy.
Main Results:
- Adjuvant therapies have historically yielded limited success in pancreatic cancer.
- Neoadjuvant strategies are increasingly investigated but lack comparative randomized trials.
- No large multicenter trials specifically for neoadjuvant pancreatic cancer therapy exist.
Conclusions:
- Neoadjuvant therapy presents a promising avenue for pancreatic cancer treatment.
- Further investigation and comparative trials are essential to validate neoadjuvant approaches.
- The development of neoadjuvant strategies aims to improve upon the limitations of current treatment paradigms.
